Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
4
67%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Not yet recruiting3
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting350%
completed117%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

NCT07290894
not_yet_recruitingphase_2

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

NCT05106127
not_yet_recruitingphase_3

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

NCT05077215
not_yet_recruitingphase_1

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

NCT07096609
completedphase_2

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

NCT05101629
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07290894Phase 2

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

Recruiting
NCT05106127Phase 2

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Not Yet Recruiting
NCT05077215Phase 3

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Not Yet Recruiting
NCT07096609Phase 1

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

Not Yet Recruiting
NCT05101629Phase 2

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Completed
NCT06739395Phase 2

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6